A semisynthetic glycoconjugate provides expanded cross-serotype protection 
against Streptococcus pneumoniae

Kaplonek, Paulina; Yao, Ling; Reppe, Katrin; Voß, Franziska; Kohler, Thomas; Ebner, Friederike; Schäfer, Alexander; Blohm, Ulrike; Priegue, Patricia; Bräutigam, Maria; Pereira, Claney Lebev; Parameswarappa, Sharavathi Guddehalli; Emmadi, Madhu; Ménová, Petra; Witzenrath, Martin; Hammerschmidt, Sven; Hartmann, Susanne; Sander, Leif E.; Seeberger, Peter H.

doi:10.1016/j.vaccine.2021.12.068

Datensatz

DATENSATZ AKTIONENEXPORT

Zur Ablage hinzufügen

Lokale TagsFreigabegeschichteDetailsÜbersicht

Freigegeben

Zeitschriftenartikel

A semisynthetic glycoconjugate provides expanded cross-serotype protection against Streptococcus pneumoniae

MPG-Autoren

/persons/resource/persons203549

Kaplonek, Paulina
Peter H. Seeberger - Vaccine Development, Biomolekulare Systeme, Max Planck Institute of Colloids and Interfaces, Max Planck Society;

/persons/resource/persons268736

Yao, Ling
Peter H. Seeberger - Vaccine Development, Biomolekulare Systeme, Max Planck Institute of Colloids and Interfaces, Max Planck Society;

/persons/resource/persons251980

Priegue, Patricia
Peter H. Seeberger - Vaccine Development, Biomolekulare Systeme, Max Planck Institute of Colloids and Interfaces, Max Planck Society;

/persons/resource/persons239941

Bräutigam, Maria
Peter H. Seeberger - Vaccine Development, Biomolekulare Systeme, Max Planck Institute of Colloids and Interfaces, Max Planck Society;

/persons/resource/persons121719

Pereira, Claney Lebev
Peter H. Seeberger - Vaccine Development, Biomolekulare Systeme, Max Planck Institute of Colloids and Interfaces, Max Planck Society;

/persons/resource/persons188901

Parameswarappa, Sharavathi Guddehalli
Peter H. Seeberger - Vaccine Development, Biomolekulare Systeme, Max Planck Institute of Colloids and Interfaces, Max Planck Society;

/persons/resource/persons209014

Emmadi, Madhu
Peter H. Seeberger - Vaccine Development, Biomolekulare Systeme, Max Planck Institute of Colloids and Interfaces, Max Planck Society;

/persons/resource/persons200004

Ménová, Petra
Peter H. Seeberger - Vaccine Development, Biomolekulare Systeme, Max Planck Institute of Colloids and Interfaces, Max Planck Society;

/persons/resource/persons121849

Seeberger, Peter H.
Peter H. Seeberger - Vaccine Development, Biomolekulare Systeme, Max Planck Institute of Colloids and Interfaces, Max Planck Society;

Externe Ressourcen

Es sind keine externen Ressourcen hinterlegt

Volltexte (beschränkter Zugriff)

Für Ihren IP-Bereich sind aktuell keine Volltexte freigegeben.

Volltexte (frei zugänglich)

Preprint.pdf
(Preprint), 528KB

Ergänzendes Material (frei zugänglich)

Es sind keine frei zugänglichen Ergänzenden Materialien verfügbar

Zitation

Kaplonek, P., Yao, L., Reppe, K., Voß, F., Kohler, T., Ebner, F., et al. (2022). A semisynthetic glycoconjugate provides expanded cross-serotype protection against Streptococcus pneumoniae. Vaccine. doi:10.1016/j.vaccine.2021.12.068.

Zitierlink: https://hdl.handle.net/21.11116/0000-0009-D251-E

Zusammenfassung

Streptococcus pneumoniae (S. pneumoniae) infections are the leading cause of child mortality globally. Current vaccines fail to induce a protective immune response towards a conserved part of the pathogen, resulting in new serotypes causing disease. Therefore, new vaccine strategies are urgently needed. Described is a two-pronged approach combining S. pneumoniae proteins, pneumolysin (Ply) and pneumococcal surface protein A (PspA), with a precisely defined synthetic oligosaccharide, whereby the carrier protein acts as a serotype-independent antigen to provide additional protection. Proof of concept in mice and swine models revealed that the conjugates inhibited colonization of the nasopharynx, decreased the bacterial load and reduced disease severity in the bacteria challenge model. Immunization of piglets provided the first evidence for the immunogenicity and protective potential of synthetic glycoconjugate vaccine in a large animal model. A combination of synthetic oligosaccharides with proteins from the target pathogen opens the path to create broadly cross-protective (“universal”) pneumococcal vaccines.